KRAS and lung carcinoma: Moreover, a large scale phase III clinical trial (Galaxy-2) in advanced lung cancer examining the combination of ganetespib and docetaxel failed to demonstrate either a PFS or OS benefit in either KRAS mutant or KRAS wild type NSCLC patients [273].